Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Travere Therapeutics, Inc. (RTRX)
|
Add to portfolio |
|
|
|
| Price: |
$30.60
| | Metrics |
| OS: |
75.0
|
M
| |
|
|
| Market cap: |
$2.3
|
B
| |
|
|
|
Net cash:
|
$115
|
M
| |
$1.53
|
per share
|
|
EV:
|
$2.18
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 212.0 | 227.5 | 198.3 | 175.3 | 164.2 | 154.9 | 138.1 | 99.9 |
| Revenue growth | -6.8% | 14.7% | 13.1% | 6.8% | 6.0% | 12.2% | 38.3% | 254.2% |
| Cost of goods sold | 7.6 | 6.8 | 6.1 | 5.2 | 5.5 | 3.6 | 4.6 | 2.2 |
| Gross profit | 204.4 | 220.7 | 192.2 | 170.1 | 158.7 | 151.3 | 133.6 | 97.7 |
| Gross margin | 96.4% | 97.0% | 96.9% | 97.0% | 96.6% | 97.7% | 96.7% | 97.8% |
| Selling, general and administrative | 220.2 | 149.9 | 135.8 | 129.0 | 103.7 | 101.3 | 91.9 | 79.5 |
| Research and development | 235.8 | 210.3 | 131.8 | 141.0 | 123.8 | 78.2 | 70.8 | 50.4 |
| EBITA | -220.6 | -114.6 | -52.9 | -77.1 | -50.7 | -10.8 | -17.7 | -159.0 |
| EBITA margin | -104.0% | -50.4% | -26.7% | -44.0% | -30.8% | -7.0% | -12.8% | -159.2% |
| Amortization of intangibles | 31.0 | 24.9 | 22.4 | 19.7 | 18.0 | 17.3 | 16.0 | 13.2 |
| EBIT | -251.6 | -139.5 | -75.4 | -96.8 | -68.7 | -28.2 | -33.7 | -172.3 |
| EBIT margin | -118.7% | -61.3% | -38.0% | -55.2% | -41.8% | -18.2% | -24.4% | -172.5% |
| Pre-tax income | -278.2 | -179.7 | -188.8 | -146.4 | -101.9 | -58.4 | -57.6 | 105.5 |
| Income taxes | 0.3 | 0.4 | -19.4 | 0.0 | 0.8 | 1.4 | -9.7 | -11.8 |
| Tax rate | | | 10.3% | 0.0% | | | 16.8% | |
| Net income | -278.5 | -180.1 | -169.4 | -146.4 | -102.7 | -59.7 | -47.9 | 117.2 |
| Net margin | -131.3% | -79.2% | -85.4% | -83.5% | -62.5% | -38.6% | -34.7% | 117.4% |
| |
| Diluted EPS | ($4.37) | ($3.01) | ($3.56) | ($3.46) | ($2.54) | ($1.54) | ($1.25) | $3.12 |
| Shares outstanding (diluted) | 63.8 | 59.8 | 47.5 | 42.3 | 40.4 | 38.8 | 38.3 | 37.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|